Interaction of memantine and ketamine in morphine- and pentazocine-induced antinociception in mice

Pharmacological Reports

Volumn 60, Issue 2, 2008, Pages 149-155

  Malec, Danuta ^a   Mandryk, Marcin ^a   Fidecka, Sylwia ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antinociception; Ketamine; Memantine; Mice; Morphine; Pentazocine

Indexed keywords

KETANEST; MEMANTINE; MORPHINE; PENTAZOCINE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; MALE; MONOTHERAPY; MOTOR COORDINATION; MOUSE; NONHUMAN; WRITHING TEST;

EID: 49749134360     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Abdel Salam OME: Vinpocetine and piracetam exert antinociceptive affect in visceral pain model in mice. Pharmacol Rep, 2006, 58, 680-691.
2. Baker AK, Hoffmann VLH, Meert TF: Dextromethorphan and ketamine potentiate the antinociceptive effects of μ- but not δ- or κ-opioid agonists in a mouse model of acute pain. Pharmacol Biochem Behav, 2002, 74, 73-86.
3. Bell RF: Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain, 1999, 83, 101-103.
4. Bell RF, Eccleston Ch, Kalso E: Ketamine as adjuvant to opioids for cancer pain. A quantitative systematic review. J Pain Symptom Manag, 2003, 26, 867-875.
5. Belozertseva IV, Dravolina OA, Neznanova ON, Danysz W, Bespalov AY: Antinociceptive activity of combination of morphine and NMDA receptor antagonists depends on the inter-injection interval. Eur J Pharmacol, 2000, 396, 77-83.
6. Bilsky EJ, Inturrisi CE, Sadee W, Hruby VJ, Porreca F: Competitive and noncompetitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective μ or δ opioid antagonists in mice. Pain, 1996, 68, 229-237.
7. Boissier JR, Tardy J, Diverres JC: Une nouvelle méthode simple pour explorer l'action 'tranquillisante: le test de la chemine. Med Exp (Basel), 1960, 3, 81-84.
8. Chen SL, Huang EY, Chow LH, Tao PL: Dextromethorphan differentially affects opioid antinociception in rats. Br J Pharmacol, 2005, 144, 400-404.
9. Dambisya YM, Lee TL: Antinociceptive effects of ketamine-opioid combinations in the mouse tail-flick test. Methods Find Exp Clin Pharmacol, 1994, 16, 179-184.
10. Dickenson AH, Ayder E: Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the rat. Neurosci Lett, 1991, 121, 263-266.
11. Dogrul A, Deniz G: The analgesic effect of amlodipine and its interaction with morphine, ketorolac and naloxone after peripheral and central administration in mice. Eur Neuropsychopharmacol, 1996, 6. Suppl 1, s 30.
12. Dunbar S, Yaksu TL: Concurrent spinal infusion of MK-801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Anesthesiology, 1996, 84, 1177-1188.
13. Eisenberg E, LaCross S, Strassman AM: The effects of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats Eur J Pharmacol, 1994, 255, 123-129.
14. Eisenberg E, LaCross S, Strassman AM: The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Neurosci Lett, 1995, 187, 17-20.
15. Eisenberg E, Vos BP, Strassman AM: The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain. Pain, 1993, 54, 301-307.
16. Fidecka S, Pirogowicz E: Lack of interaction between the behavioral effects of ketamine and benzodiazepines in mice. Pol J Pharamacol, 2002, 54, 111-117.
17. Fine PG: Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manag, 1999, 17, 296-300.
18. Fisher K, Coderre TJ, Hagen NA: Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage, 2000, 20, 358-373.
19. Gutstein HB, Akil H: Opioid analgesics. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn, Ed. Brunton LL, Lazo JS, Parker KL, McGraw Hill, USA, 2006, 547-590.
20. Koster R, Anderson M, de Beer EJ: Acetic acid for analgesic screening. Fred Proc, 1959, 18, 412.
21. Kozela E, Danysz W, Popik P: Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw in rats. Eur J Pharmacol, 2001, 423, 17-26.
22. Le Bars D, Gozariu M, Cadden SW: Animal models of nociception. Pharmacol Rev, 2001, 53, 597-652.
23. Lutfy K, Hurlbut DE, Weber E: Blockade of morphine-induced analgesia and tolerance in mice by NM-801. Brain Res, 1993, 616, 83-88.
24. Lutfy K, Shen K-Z, Woodward RM, Weber E: Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. Brain Res, 1996, 731, 171-181.
25. Marek P, Ben-Eliyahu S, Gold M, Liebeskhad JC: Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res, 1991, 547, 77-81.
26. Miranda HF, Puig MM, Dursteler C, Prieto JC, Pinardi G: Dexketoprofen-induced antinociception in animal models of acute pain: synergy with morphine and paracetamol. Neuropharmacology, 2007, 52, 291-296.
27. Näsström J, Karlsson U, Post C: Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice. Eur J Pharmacol, 1992, 212, 21-29.
28. Nemmani KVS, Grisel JE, Stowe JR, Smith-Carliss R, Mogil JS: Modulation of morphine analgesia by site-specific N-methyl-D-aspartate receptor antagonists: dependence on sex, site of antagonism, morphine dose, and time. Pain, 2004, 109, 274-283.
29. Neugebauer V, Kornhuber J, Lücke T, Schaible HG: The clinically available NMDA receptor antagonist memantine is antinociceptive on rat spinal neurons. Neuroreport, 1993, 4, 1259-1262.
30. Parsons CG, Danysz W, Quack G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuro-pharmacology, 1999, 38, 735-767.
31. Raigorodsky G, Urca G: Spinal antinociceptive effects of excitatory amino acid antagonists: quisqualate modulates the action of N-methyl-D-aspartate. Eur J Pharmacol, 1990, 182, 37-47.
32. Schley M, Topfer S, Wiech K, Schaller HE, Konrad CJ, Schmelz M, Birbaumer N: Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. Eur J Pain, 2007, 11, 299-308.
33. Svenson JE, Abernathy MK: Ketamine for prehospital use: new look at an old drug. Am J Emerg Med, 2007, 25, 977-980.
34. Tiseo PJ, Cheng J, Pasternak GW, Inturrisi CE: Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY 274614: assessment of opioid receptor changes. J Pharmacol Exp Ther, 1994, 268, 195-201.
35. Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 1991, 251, 85-87.
36. Vaccarino AL, Marek O, Kest B, Weber E, Keana JFW, Liebeskind JC: NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res, 1993, 615, 331-334.
37. Vogel HG, Vogel WH: Drug Discovery and Evaluation. Pharmacological Assays. Springer-Verlag, Berlin, Heidelberg, 1997, 360-420.
38. Webb AR, Skinner BS, Leong S, Kolawole H, Crofts T, Taverner M, Burn SJ: The addition of a small-dose ketamine infusion to tramadol for postoperative analgesia: a double-blinded, placebo-controlled, randomized trial after abdominal surgery. Anesth Analg, 2007, 104, 912-917.
39. White PF, Way WL, Trevor AJ: Ketamine - its pharmacology and therapeutic uses. Anesthesiology, 1982, 56, 119-136.